SCHEMBL735609

SCHEMBL735609

COC(=O)[C@H](CCO)N1CCN(c2ccc(Cl)c(Cl)c2)CCC1=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.50
SMN1; SMN2 Q16637 5/20 0.50
RAB9A P51151 1/20 0.49
HTT P42858 3/20 0.48
MAPK1 P28482 1/20 0.48
TP53 P04637 2/20 0.41
PANK3 Q9H999 1/20 0.41
ALDH1A1 P00352 2/20 0.41
KDM4E B2RXH2 1/20 0.41
GRIN1 Q05586 2/20 0.41
GRIN2B Q13224 2/20 0.41
POLB P06746 1/20 0.40
KDM6B O15054 1/20 0.40
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
ADAMTS5 Q9UNA0 2/20 0.40
MMP2 P08253 1/20 0.40
LMNA P02545 1/20 0.40
RECQL P46063 1/20 0.40
BCL2A1 Q16548 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL735610 1.00 MAPT (0.50) MAPTSMN1; SMN2RAB9AHTTMAPK1
SCHEMBL734542 0.87 MAPT (0.52) MAPTSMN1; SMN2RAB9AHTTMAPK1
SCHEMBL734543 0.87 MAPT (0.52) MAPTSMN1; SMN2RAB9AHTTMAPK1
SCHEMBL735104 0.84 LMNA (0.46) MAPTSMN1; SMN2RAB9AHTTMAPK1
SCHEMBL735105 0.84 LMNA (0.46) MAPTSMN1; SMN2RAB9AHTTMAPK1
SCHEMBL734899 0.84 GFER (0.45) MAPTSMN1; SMN2RAB9AHTTMAPK1
SCHEMBL734898 0.84 GFER (0.45) MAPTSMN1; SMN2RAB9AHTTMAPK1
SCHEMBL733683 0.83 ADAMTS5 (0.42) MAPTSMN1; SMN2RAB9AALDH1A1KDM4E
SCHEMBL733682 0.83 ADAMTS5 (0.42) MAPTSMN1; SMN2RAB9AALDH1A1KDM4E
SCHEMBL734549 0.81 RAB9A (0.42) MAPTSMN1; SMN2RAB9AHTTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8138175-B2 Heterocyclyl compounds HOFFMANN-LA ROCHE INC. (US) 2012-03-20 US disclosed
EP-2321285-A1 DIAZEPAN AND PIPERAZINE DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS F. Hoffmann-La Roche AG (CH) 2011-05-18 EP disclosed
WO-2010012619-A1 DIAZEPAN AND PIPERAZINE DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS F. HOFFMANN-LA ROCHE AG (CH) 2010-02-04 WO disclosed
US-20100022518-A1 NOVEL HETEROCYCLYL COMPOUNDS HOFFMANN-LA ROCHE, INC. 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022518-A1 NOVEL HETEROCYCLYL COMPOUNDS CCR2, CCR3, CCR5 MAPT 4751/4885SMN1; SMN2 4455/4885RAB9A 762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.